Tempus ECG-AF vs KardiaAI
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older, without a prior AF diagnosis, who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months, leveraging standard 12-lead ECG recordings. This tool is ideal for integration into existing healthcare facility systems to enhance risk stratification and guide earlier preventative follow-up within a clinical setting.
View Tempus ECG-AF →Choose KardiaAI if…
Choose KardiaAI if you need a flexible, AI-powered software library to analyze ambulatory ECG rhythms for the detection of a wide range of existing cardiac conditions, including AFib, bradycardia, and tachycardia. This solution is best suited for integration into mobile applications, wearable devices, or remote patient monitoring platforms, enabling on-demand or continuous heart rhythm analysis outside of a traditional clinical setting.
View KardiaAI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | KardiaAI |
|---|---|---|
| Pricing | Contact vendor | Subscription-based for advanced features and services. |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Mobile app, cloud-based. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
KardiaAIKardiaAI offers a more flexible and accessible user experience through its integration into mobile apps and web platforms, catering to individual clinicians and remote patient monitoring. In contrast, Tempus ECG-AF is designed for deep backend integration into healthcare facility systems without a dedicated user interface, making its direct usability for a broad audience less apparent.
Clinical Value
KardiaAIWhile Tempus ECG-AF provides significant predictive value by identifying patients at risk of developing AF within 12 months, a crucial step for proactive care, KardiaAI offers a broader range of immediate diagnostic capabilities for multiple cardiac conditions, including AFib, bradycardia, tachycardia, and with its newer KAI 12L AI, even acute myocardial infarction and ischemia from a reduced leadset. This comprehensive and immediate diagnostic utility across a wider array of conditions provides broader clinical impact.
Pricing & Value
KardiaAIKardiaAI provides transparent, subscription-based pricing that is accessible for individual clinicians and smaller practices, offering clear value for its range of diagnostic features. Tempus ECG-AF requires direct vendor contact for pricing, indicating a higher, enterprise-level cost, although it benefits from established CMS reimbursement codes for institutions. KardiaAI's transparent and lower-cost model offers superior value for a broader market.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF is explicitly designed for deep integration into healthcare facility systems and EHRs, focusing on large-scale institutional workflows and leveraging a massive training dataset of over 1.5 million ECGs. While KardiaAI also offers robust API and SDK integrations for enterprises and partnerships for EHR integration, its deployment strategy also includes a strong consumer/individual clinician focus. Tempus's direct system integration and focus on health systems give it an edge in deep, centralized enterprise deployment.
Innovation
Tempus ECG-AFTempus ECG-AF demonstrates a higher level of innovation by applying AI to *predict* the risk of future atrial fibrillation within 12 months from a standard ECG, representing a significant advancement in proactive and preventative cardiovascular care. While KardiaAI is innovative in democratizing access to medical-grade ECG analysis and offering a broad range of *diagnostic* detections, Tempus's predictive capability moves beyond traditional diagnostic enhancement.
Support & Docs
KardiaAIKardiaAI provides publicly accessible support channels, including phone and email contact information, dedicated support pages with FAQs, and comprehensive API documentation for developers. Tempus ECG-AF lacks publicly available information regarding customer support or detailed documentation, suggesting that support is primarily handled through enterprise-level agreements and integrations, which is less transparent for general users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | KardiaAI |
|---|---|---|
| Name | Tempus ECG-AF | KardiaAI |
| Company | Tempus AI, Inc. | AliveCor |
| Description | Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | KardiaAI by AliveCor is an FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia. |
| Key Detections | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months | Detection of atrial fibrillation, bradycardia, tachycardia, and normal sinus rhythm. Detection of Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE). |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery | Not specified |
| ECG Lead Type | 12-lead ECG recordings | Ambulatory ECG rhythms; compatible with 6-lead personal ECG devices like KardiaMobile 6L |
| Training Data | Trained on over 1.5 million ECGs from over 500,000 patients | Trained and validated on more than 1.75 million ECGs from leading US medical centers (for KAI 12L AI technology) |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and KardiaAI.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or KardiaAI
Backers
Who funded each tool's parent company.